Lori Croft, MD
Cardiovascular Disease · New York, NYNPI 1336140631
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Lantheus Medical Imaging, Inc. accounts for 86.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2020 at $10,626 and has fallen 93.9% since, to $650 in 2025.
Across 78 payments — averaging $171.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lantheus Medical Imaging, Inc.$12K
- Novo Nordisk$342
- Abbott$282
- Novartis$216
- Johnson & Johnson$193
- Amgen$180
- plus $651 from 11 others
What the payments were for
- Consulting fees$6,00045%
- Speaking & faculty fees$4,50034%
- Travel & lodging$5444%
- Food & beverage$2,35718%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lantheus Medical Imaging, Inc. | 15 | $11,537 |
| Novo Nordisk | 17 | $342 |
| Abbott | 2 | $282 |
| Novartis | 9 | $216 |
| Johnson & Johnson | 3 | $193 |
| Amgen | 7 | $180 |
| Philips North America LLC | 3 | $174 |
| Pfizer | 7 | $116 |
| E.r. Squibb & Sons, L.L.C. | 3 | $84 |
| Heartflow, Inc. | 3 | $76 |
| Boehringer Ingelheim | 2 | $42 |
| AstraZeneca | 2 | $41 |
| Esperion Therapeutics, Inc. | 1 | $29 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Boston Scientific | 1 | $25 |
| Lilly USA, LLC | 1 | $20 |
| GE HealthCare | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Definity$11,252
- MitraClip$282
- XARELTO$150
- (5044) MCOT$102
How this compares
$13,401 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Labetalol Hcl | 11 | $395 |
| Rosuvastatin Calcium | 20 | $222 |
| Atorvastatin Calcium | 31 | $152 |
| Montelukast Sodium | 13 | $83 |
| Amlodipine Besylate | 23 | $75 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.